Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry - 02/09/11
, Joel Charrow, MD b, Hans C Andersson, MD c, Paige Kaplan, MD d, Edwin H Kolodny, MD e, Pramod Mistry, MD f, Gregory Pastores, MD e, Barry E Rosenbloom, MD g, C.Ronald Scott, MD h, Rebecca S Wappner, MD i, Ari Zimran, MD jAbstract |
Purpose |
Gaucher disease is the first lysosomal storage disorder to be treated with macrophage-targeted enzyme replacement therapy. Previous studies in relatively small numbers of patients demonstrated short-term efficacy of this treatment. This study describes the effects of 2 to 5 years of treatment on specific manifestations of type 1 Gaucher disease.
Subjects and methods |
Physicians reported data from 1028 patients to the Gaucher Registry. Assessment of response included serial measurements of hemoglobin concentration, platelet count, liver and spleen volumes, and the occurrence of bone pain and bone crises.
Results |
Among anemic patients, hemoglobin concentration increased to normal or near normal within 6 to 12 months, with a sustained response through 5 years. In thrombocytopenic patients with intact spleens, the most rapid response occurred during the first 2 years, with slower improvement thereafter. The likelihood of achieving a normal platelet count decreased with increasing severity of baseline thrombocytopenia. In patients who had undergone splenectomy, platelet counts returned to normal within 6 to 12 months. Hepatomegaly decreased by 30% to 40% during follow-up; splenomegaly decreased 50% to 60%, but rarely to volumes below five times normal size. In patients with pretreatment bone pain or bone crises, 52% (67/128) were pain free after 2 years and 94% (48/51) reported no additional crises.
Conclusion |
Enzyme replacement therapy prevents progressive manifestations of Gaucher disease, and ameliorates Gaucher disease–associated anemia, thrombocytopenia, organomegaly, bone pain, and bone crises.
Le texte complet de cet article est disponible en PDF.Keywords : Gaucher disease, enzyme replacement therapy, imiglucerase, Gaucher Registry, lysosomal storage disorder
Plan
 | This study was supported in part by a grant from Genzyme Corporation, Cambridge, Massachusetts. The Gaucher Registry is sponsored by Genzyme Corporation. |
Vol 113 - N° 2
P. 112-119 - août 2002 Retour au numéro
Article précédent
- An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase
- David M Kent, Rodney A Hayward, John L Griffith, Sandeep Vijan, Joni R Beshansky, Robert M Califf, Harry P Selker
- The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections
- Roman Pallares, Olga Capdevila, Josefina Liñares, Imma Grau, Hisao Onaga, Fe Tubau, Marco H Schulze, Peter Hohl, Francesc Gudiol
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?